Comparative Pharmacology
Head-to-head clinical analysis: IOSAT versus THYROSHIELD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOSAT versus THYROSHIELD.
IOSAT vs THYROSHIELD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks thyroidal uptake of radioactive iodine isotopes, reduces thyroid exposure to radiation by saturating thyroid gland with stable iodine.
Thyroshield (potassium iodide) acts by supplying excess iodide, which inhibits thyroid hormone synthesis via the Wolff-Chaikoff effect, blocks thyroidal iodide uptake, and reduces thyroid vascularity. It also protects the thyroid from radioactive iodine uptake by saturating iodine transport and organification mechanisms.
Adults: 130 mg orally once daily for potassium iodide (SSKI 1 g/mL). For thyroid protection in radiation exposure: 130 mg orally once, may repeat after 24 hours if necessary.
Intravenous: Loading dose 200 mg, then 50 mg every 6 hours; or continuous infusion: 200 mg bolus then 800 mg over 24 hours. Oral: 50 mg every 6 hours.
None Documented
None Documented
3-5 days in euthyroid individuals; prolonged in hyperthyroidism (6-12 days) and renal impairment (up to 30 days)
Terminal elimination half-life is 12-24 hours; clinical effect persists 24-36 hours after single dose.
Renal: >99% as iodide; fecal/biliary: <1%
Primarily renal (90-95% unchanged), minor biliary/fecal (5-10%).
Category C
Category C
Antithyroid Agent
Antithyroid Agent